Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: Pooled analysis of week 16 data from 3 randomized controlled trials
Journal of the European Academy of Dermatology and Venereology | Sep 28, 2018
Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: An integrated analysis from 11 clinical trials
Journal of the European Academy of Dermatology and Venereology | Sep 15, 2018
Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)
Journal of the European Academy of Dermatology and Venereology | Aug 30, 2018
Most read this week